Comment: Why does Shenzhen choose the biomedical industry

China Well -off Network Exclusive Specialty

Wen | Ma Chunhui

According to the current status of the development of the biomedical industry in Shenzhen, how does the future biomedical industry develop? On the basis of market guidance, the government supports biomedical companies to strengthen and grow.

The biomedical industry is an industry with capital -intensive and technical intensive integration. The biggest advantage of Shenzhen in developing the biomedical industry is the advantages of funds, because Shenzhen is already an important capital market in my country and Southeast Asia. Support the development of strategic emerging industries. As a strategic emerging industry in Shenzhen, the biomedical industry has a better development momentum, but the scale of the industry is relatively small, which is not proportional to Shenzhen's economic aggregate. In 2021, Shenzhen's strategic emerging industries added a total of 1214.637 billion yuan, an increase of 6.7%over the previous year, accounting for 39.6%of the regional GDP. The value -added of the biomedical and the health industry was 58.96 billion yuan, accounting for only 4.85%of the proportion of strategic emerging industries, 1.9%of the regional GDP, and the growth rate was relatively slow. In 2021, it only increased by 7.6%. Shenzhen biomedical enterprises are not prominent, leading enterprises have not obvious role in the industry, and there are not many well -known products and core technologies with international influence. Mai Rui is a well -known enterprise in the field of high -end medical device and equipment in Shenzhen. The company's turnover of this company is only more than 25 billion yuan. Among the more than 200 billion operating income, foreign markets only account for more than 40%, and the domestic market accounts for 50%. many. As a listed company, the market value of Mindray is only more than 300 billion yuan. Such a scale can only be regarded as a well -known large -scale medical device and equipment supplier internationally, and it is not a world -renowned large enterprise. Huada Gene is also a typical biomedical high -tech listed company. Huada Gene Company is famous. In fact, its output value is not very large. In 2021, the total revenue was only 6.7 billion yuan. Neptune Bio is a typical biomedical listed company. In 2021, sales revenue was more than 40 billion yuan, and the company's products were worth more than 600 million. Others were outsourced products.

The biomedical industry has a characteristic of technology, that is, technological innovation and product innovation are very slow. Whether it is a medical product or a medical device product, the innovation cycle is relatively long, and it is difficult to form an industrial cluster effect. If there is an industrial cluster, it can only be gathered by large biomedical enterprises.

According to the current status of the development of the biomedical industry in Shenzhen, how does the future biomedical industry develop? First, on the basis of market guidance, the government supports biomedical companies to strengthen and grow. Shenzhen has initially formed the agglomeration effect of the development of the biomedical industry, but there are shortcomings with poor innovation capabilities. Therefore, the government needs to support enterprises for product innovation, technological innovation, open up international markets, follow the path of international development, and promote the stronger and bigger biomedical enterprises. Second, the government can introduce a group of large biopharmaceutical multinational companies in the introduction of foreign capital to support the development and agglomeration of Shenzhen biomedical industry by borrowing external forces. The experience of developing the biomedical industry in Singapore is worthy of reference. The output value of Singapore's biopharmaceutical industry has doubled in the past 20 years and contributed 18%of Singapore's manufacturing GDP. In 2021, biomedical manufacturing generally increased by 11.1%. From 0 to the market volume of tens of billions of dollars, how does Singapore do? The experience of the success of Singapore's biomedical industry is to adopt the "focusing factory" innovative development model. Production and operating expert Wickham Skinner uses the word "focusing factory" in an HBR article published in 1974, defining the innovative model of "focusing factory" = clear strategic intent+infrastructure+high -density talents. As of 2020, 11 world -class pharmaceuticals and biotechnology companies including Grammcsk, Merhado, Abervi, Novartis, Pfizer, Roche, Sanofi, Anshin, etc. have invested in Singapore. 25 large -scale innovation research bases include the cutting -edge fields such as clinical science, genomics, biological engineering, cell biology, pharmaceutical biology, biological imaging, and immunology. The introduction of a large number of multinational companies directly drives the gathering effect of Singapore's biomedical industry. Third, the government should provide technical support for the development of the biomedical industry. The technology research and development investment of the biomedical industry is large, risky, long -term, and the industrialization is relatively slow. There are great uncertainty and risks in enterprise investment. my country's biomedical industry has not developed for a long time, and its technology is backward. It is difficult to occupy the power of the industry's technical system. In this market failure, the government needs to invest in R & D. Shenzhen can set up a government biomedical industry R & D fund, which can introduce dozens of biomedical research and development institutions to support scientific research institutions to engage in research and development of major biomedicine, and form a long -term mechanism for biomedical research and development. The results developed by the government supported by the government belonged to the government, transferred by the government, or participated in the industrialization process as government shares. This is also an important choice to support the development of the biomedical industry.

(Author is an associate professor in Shenzhen University)

("Well -off" · China Well -off Exclusive Draft)

This article was published in "Well -off" in late August 2022

- END -